[Clostridium perfringens and gas gangrene].
Lindsay
D
D
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001427:Bacterial Toxins / Q000378:metabolism; D001431:Bacteriological Techniques; D002135:Calcium-Binding Proteins; D003016:Clostridium perfringens / Q000472:pathogenicity; D004359:Drug Therapy, Combination; D005738:Gas Gangrene / Q000175:diagnosis* / Q000188:drug therapy; D006801:Humans; D009132:Muscles / Q000382:microbiology; D013530:Surgical Wound Infection / Q000175:diagnosis* / Q000188:drug therapy; D010738:Type C Phospholipases; D014774:Virulence
D000900:Anti-Bacterial Agents; D001427:Bacterial Toxins; D002135:Calcium-Binding Proteins; D010738:Type C Phospholipases; C040649:alpha toxin, Clostridium perfringens
Clostridium perfringens und Gasbrand.